HIRA clarifies ‘Opdivo·Keytruda·Tecentriq’ eligibility

By Lee, Hye-Kyung | translator Alice Kang

21.10.29 12:00:15

가나다라 0

Confusion arose on reimbursement eligibility due to the deletion of cancer stages in the course of amending category 1 and 2 anticancer agents for NSCLC

Phrase ‘Stage ⅢB or higher’ was added to second-line or subsequent lines of treatment in NSCLC

The 'Stage ⅢB or higher’ phrase was added to the subjects eligible for reimbursement of ‘Opdivo (nivolumab),’ ‘Keytruda (pembrolizumab),’ and ‘Tecentriq (atezolizumab)’ in NSCLC.

The Health Insurance Review and Assessment Service announced that it will implement the ‘Amendment to the Notice on Drugs Prescribed and Administered to Cancer Patients' which will take effect from November 1.

The amendment was made to address the confusion that arose regarding the eligibility of reimbursement after the cancer stage criteria were deleted in subjects for immunotherapy as second-line or subsequent lines of palliative therapy on May 1st.

HIRA added the 'Stage ⅢB or higher�

Lee, Hye-Kyung(hgrace7@dailypharm.com)

If you want to see the full article, please JOIN US (click)